100% Locally Owned, Independent and Free

100% Locally Owned, Independent and Free

Trial could be significant step forward in pursuit of new treatment for autoimmune disease

Do you have a news tip? Click here to send to our news team.

Fishing report: Jasper’s big reef haul

We've finally enjoyed a run of good weather, with beautiful sunny days and minimal wind. The weather is looking pretty good for the coming weekend More

Major bank to relocate town’s only branch

A big four bank is set to relocate its only remaining branch in a busy town, meaning customers will need to go to the More

Upgrades for three busy intersections on main road

Works have started on improving a trio of intersections on bustling Nicklin Way. The upgrades are set to help reduce congestion and the potential for More

Crane arrival marks new heights for hospital construction

The skyline of new Maroochydore CBD is transforming with the arrival of a tower crane on the Maroochy Private Hospital construction site, marking another More

New deputy mayor appointed as Natoli makes first address

The new Sunshine Coast Council has held its post-election meeting, with Councillor Maria Suarez to serve as the region’s new deputy mayor. Cr Suarez, who More

Photo of the day: sunrise reflections

Sunrise at Mooloolaba Beach, by Helen Browne. If you have a photo of the day offering, email photo@sunshinecoastnews.com.au. Photos must be horizontal/landscape and may need More

A potential new treatment for rheumatoid arthritis will be tested on the Sunshine Coast.

The University of the Sunshine Coast Clinical Trials and Servatus Biopharmaceuticals Ltd are collaborating to trial a live biotherapeutic product, which is a field of medical therapy that is advancing globally.

Principal investigator Dr Peter de Wet said rheumatoid arthritis was an autoimmune disease that occurred when the immune system mistakenly attacked the body’s tissues, affecting the joints’ lining and causing joint pain and stiffness.

“Rheumatoid arthritis can be a debilitating condition that can impact many aspects of daily living,” he said via a UniSC media release.

“We are interested to learn about the role of the gut microbiome in treating symptoms of this condition.

“And while there are various strategies to improve joint mobility and muscle strength and reduce inflammation, some treatments are ineffective or have unwanted side effects, highlighting the need for new medicines to address the condition.”

He said the trial, to be held at UniSC’s newest clinic at Birtinya, represented a significant step forward in the pursuit of a new treatment.

Clinical Trials coordinator Jacinta Trevaskis.

Dr Samantha Coulson, head of clinical research at Servatus, said the live biotherapeutic product was an exciting and promising field of medical therapies that was advancing quickly on a global scale.

Servatus has isolated select microbial species, and pre-clinical investigations suggest the potential medication may be effective in treating autoimmune and inflammatory conditions.

“The gut microbiome plays such a vital role in many diseased states including rheumatoid arthritis, as the gut bacteria and immune system have a bidirectional influence on each other,” Dr Coulson said.

By using well-defined bacterial strains, we hope to regulate the hyperactive immune response seen in rheumatoid arthritis with significantly less side effects as with many of the current drugs in the market.

The product that could make a difference.

The team is seeking participants aged between 18 and 80 with confirmed rheumatoid arthritis and who are experiencing daily joint pain and stiffness.

Participants will need to commit to up to six visits at the Birtinya clinic over about four months and they will be reimbursed for their time on the trial.

Those interested in volunteering can find more information at UniSC Clinical Trials.

Local journalists supporting local people. Help keep independent and fair Sunshine Coast news coming by subscribing to our FREE daily news feed. All it requires is your name and email at the bottom of this article.

[scn_go_back_button] Return Home

Subscribe to SCN’s daily news email

This field is for validation purposes and should be left unchanged.